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Abstract
Background: Isolation of recombinant antibody fragments from antibody libraries is well established
using technologies such as phage display. Phage display vectors are ideal for efficient display of antibody
fragments on the surface of bacteriophage particles. However, they are often inefficient for expression of
soluble antibody fragments, and sub-cloning of selected antibody populations into dedicated soluble
antibody fragment expression vectors can enhance expression.
Results: We have developed a simple vector system for expression, dimerisation and detection of
recombinant antibody fragments in the form of single chain Fvs (scFvs). Expression is driven by the T7 RNA
polymerase promoter in conjunction with the inducible lysogen strain BL21 (DE3). The system is
compatible with a simple auto-induction culture system for scFv production. As an alternative to
periplasmic expression, expression directly in the cytoplasm of a mutant strain with a more oxidising
cytoplasmic environment (Origami 2™ (DE3)) was investigated and found to be inferior to periplasmic
expression in BL21 (DE3) cells. The effect on yield and binding activity of fusing scFvs to the N terminus
of maltose binding protein (a solubility enhancing partner), bacterial alkaline phosphatase (a naturally
dimeric enzymatic reporter molecule), or the addition of a free C-terminal cysteine was determined.
Fusion of scFvs to the N-terminus of maltose binding protein increased scFv yield but binding activity of
the scFv was compromised. In contrast, fusion to the N-terminus of bacterial alkaline phosphatase led to
an improved performance. Alkaline phosphatase provides a convenient tag allowing direct enzymatic
detection of scFv fusions within crude extracts without the need for secondary reagents. Alkaline
phosphatase also drives dimerisation of the scFv leading to an improvement in performance compared to
monovalent constructs. This is illustrated by ELISA, western blot and immunohistochemistry.
Conclusion: Nine scFv expression vectors have been generated and tested. Three vectors showed utility
for expression of functional scFv fragments. One vector, pSANG14-3F, produces scFv-alkaline
phosphatase fusion molecules which offers a simple, convenient and sensitive way of determining the
reactivity of recombinant antibody fragments in a variety of common assay systems.
Published: 07 December 2006
BMC Biotechnology 2006, 6:46 doi:10.1186/1472-6750-6-46
Received: 24 August 2006
Accepted: 07 December 2006
This article is available from: http://www.biomedcentral.com/1472-6750/6/46
© 2006 Martin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
Page 2 of 15
(page number not for citation purposes)
Background
The isolation of recombinant antibody fragments with
unique binding specificities can be readily accomplished
using antibody display methods such as phage display or
ribosome display. In such display methods large naïve
libraries are generated where the gene encoding an anti-
body is physically linked to the resulting antibody protein
(in the form of a single chain Fv fragment (scFv)). The
binding properties of the antibody fragment are then used
to isolate the encoding gene [1]. While phage display vec-
tors are designed to display recombinant antibodies on
the surface of phage, they are not necessarily optimal for
scFv expression and often selected antibody genes are sub-
cloned into a dedicated soluble antibody fragment expres-
sion vector. Sub-cloning into an expression vector is also
a requirement with ribosome display. The aim of the work
detailed in this paper is to improve the production and
utilisation of recombinant scFvs and generate a panel of
expression vectors to facilitate this. The backbone expres-
sion vector utilises the high level expression promoter
T7lac, driving expression of scFv to the bacterial periplas-
mic space via a pelB signal peptide sequence. Resultant
products are fused with a six histidine tag for one step
immobilised metal affinity chromatography (IMAC) and
a tri-FLAG epitope tag for detection.
scFv expression was performed in two Escherichia coli
strains for comparison. For standard periplasmic expres-
sion of the scFvs and their derivatives, the BL21 (DE3)
strain was used. This strain carries a chromosomal copy of
T7 RNA polymerase, under the control of the lacUV5 pro-
moter. This can be induced using IPTG or a simple auto-
induction medium as we show here. T7 RNA polymerase
can be induced resulting in expression of genes driven
from the T7lac promoter. This strain is also deficient in
both lon and ompT proteases. We also investigated expres-
sion of scFvs directly into the cytoplasm using a vector
which lacked a pelB signal peptide sequence. This was car-
ried out in an E. coli K12 derivative strain [2], which has
mutations knocking out both thioredoxin reductase (trxB)
and glutathione reductase (gor) creating a more oxidizing
cytoplasmic environment to facilitate disulphide bond
formation.
In this study we compare the expression levels and ELISA
signals from crude bacterial cell extracts of a number of C-
terminal modifications to the standard scFv format,
including a free C-terminal cysteine residue [3,4], and
maltose binding protein (MBP). MBP has previously been
shown to act as a solubility enhancing tag for recom-
binant proteins [5]. Antibody fragments were also fused
to a variant alkaline phosphatase gene with enhanced cat-
alytic activity encoded by a D153G and D330N mutation
[6,7]. The alkaline phosphatase fusion drives scFv dimeri-
sation and provides a simple enzymatic fusion partner to
facilitate direct detection of scFv fusions [6,8-10]. We
illustrate the benefit of this system in a number of com-
mon assays including ELISA, western blot and immuno-
histochemistry.
Results
Vector construction
Figure 1 shows a schematic representation of the expres-
sion cassette for each vector, and the pertinent properties
of each of the vectors are detailed in Table 1. All vectors
are driven by a T7 promoter and contain a hexa-histidine
tag for purification of scFv. The original vectors were cre-
ated with a HindIII site for tag cloning (e.g. pSANG-10,
Figure 1a) and, in the bulk of the work described here, a
tri-FLAG tag has been introduced at this site (e.g.
pSANG10-3F, Figure 1b). Figure 1c shows alternative con-
structs created from this basic backbone. Essentially there
were five different scFv expression forms: scFv only (scFv),
scFv plus a C-terminal cysteine residue (scFv-cys), scFv
fused to maltose binding protein (scFv-MBP), scFv-MBP
plus a C-terminal cysteine residue (scFv-MBP-cys), and
scFv fused to bacterial alkaline phosphatase (scFv-AP).
Additional constructs without the pelB leader sequence
(leaderless) were made in order to produce the scFv, scFv-
cys, scFv-MBP, and scFv-MBP-cys forms expressed in the
cytoplasm rather than the periplasmic space in Origami
2™ (DE3) cells. The Origami 2™ (DE3) strain is a gor/trxB
mutant which can facilitate disulphide bond formation by
creating an oxidising cytoplasmic environment.
scFv expression induced by auto-induction medium is 
equivalent to IPTG induction
Use of the T7 promoter in the pSANG vectors requires the
use of DE3 lysogen strains such as BL21 (DE3), where
there is an integrated copy of T7 RNA polymerase. Expres-
sion is controlled by the lac promoter driving expression
of T7 RNA polymerase which in turn acts on the T7 pro-
moter to induce scFv expression. The lac promoter is nor-
mally induced by the addition of IPTG in mid-log phase
growth. Studier [11] describes the development of a
growth medium-controlled induction system, which does
not require user intervention to switch on recombinant
protein expression. The growth medium contains a con-
trolled amount of carbon sources for the bacteria to utilize
for growth, and expression is tightly controlled by catabo-
lite repression. As the bacterial culture density increases
the catabolite repression is diminished by loss of the car-
bon source. When this begins, expression from the lac
promoter is turned on due to the presence of lactose in the
induction medium.
We examined the expression levels achieved with four
scFv clones expressed in both the scFv and scFv-AP for-
mats using auto-induction medium and the more stand-
ard induction medium of 2xYT supplemented with IPTG.BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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Construction of pSANG vectors Figure 1
Construction of pSANG vectors. A. Sequence of the basic vector pSANG-10, which was created by inserting an oligo 
between a BglI site (GCCnnnnnGGC) and XhoI site (CTCGAG now destroyed) downstream of the promoter within the vec-
tor backbone derived from pET26 (+) plasmid (Novagen, San Diego, CA). The inserted sequence cloned between these 
restriction sites is shown. Translated sequences from the end of the signal peptide and hexa-histidine tag are indicated. The 
scFv encoding gene is sub-cloned at the NcoI/NotI site and the HindIII site is available for insertion of peptide tags and fusion 
partners. B. For comparison the sequence of pSANG10-3F is shown where a tri-FLAG tag has been inserted. An oligonucle-
otide encoding the tri-FLAG sequence was cloned into the HindIII site of pSANG10 destroying the site at 5' end and retaining 
it at 3' end for future use. C. Schematic view of the expression cassettes of the pSANG vectors. a-d: vectors used with BL21 
(DE3) host strain for periplasmic expression. e-f: vectors used with Origami 2™ (DE3) host strain for cytoplasmic expression. 
MBP= Maltose Binding Protein; * = serine replaced by a cysteine.
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Figure 2 shows that the two systems give comparable
expression levels. The advantage of the auto-induction
medium is that optical density monitoring is not required
prior to induction. The cultures are simply inoculated and
then harvested 20 h after incubation at 30°C. For all sub-
sequent experiments auto-induction medium was used
for expression of the different scFv formats.
Effect of fusion partner and site of expression on yield of 
scFv
Antibody fragment clones specific for human collagen
type VI and human desmin were expressed in a variety of
scFv formats in two different bacterial strains. The total
and active yields of the antibody fragments were assessed
by western blot and an antigen binding ELISA respec-
tively. Each clone was grown overnight in auto-induction
medium, the bacteria pelleted and a detergent lysis per-
formed. The different scFv formats were run in SDS-PAGE
gels, blotted onto membranes and probed with an anti-
FLAG tag monoclonal antibody coupled to a fluorescent
tertiary antibody to assess both the quality and quantity of
the scFv produced. We have previously shown that fluo-
rescent western blots can be used to quantitate protein
production [5].
Densitometry was also used to quantitate the yield of each
scFv format and the data were normalised to the values
obtained for the standard scFv format expressed in BL21
(DE3) cells (summarised in Figure 3). Antigen binding
ELISAs were also carried out to determine the relative
amount of biochemically active recombinant protein in
each preparation. Figure 3 panel A shows the results
obtained for the collagen VI specific clone. In the ELISA,
the scFv-Cys format had an equivalent activity to the
standard scFv. ScFv-MBP fusion proteins were not as
active in the ELISA as the standard scFv. The addition of a
free C-terminal cysteine did not improve the activity of the
scFv-MBP format in the ELISA. Western blot analysis
revealed the reduced activity in ELISA was not due to
diminished expression levels. In fact expression levels of
both scFv-MBP fusions were far higher than the standard
monovalent scFv suggesting interference in antigen bind-
ing with scFv-MBP fusions. There was also evidence of
lower molecular weight bands which probably represent
proteolytic cleavage products. The scFv-AP format pro-
duces scFv fused to bacterial alkaline phosphatase, which
is enzymatically active only as a dimer. The ELISA activity
for this scFv-AP clone was superior to the standard scFv
and yields were also higher as determined by western blot.
Figure 3B shows the results for an anti-desmin clone. The
results for this antibody fragment clone are in broad
agreement with those obtained for the anti-collagen VI
clone. However, notably the yield and activity of the scFv-
AP format was reduced compared to the standard scFv for-
mat for this clone. A third scFv clone specific for human
HER2 was also tested in the panel of vectors and gave
broadly similar results to those obtained above (data not
shown).
All of the above clones were expressed in BL21 (DE3) cells
and the polypeptides generated are directed to the peri-
plasmic space of the bacteria by the presence of a signal
peptide sequence. Two vectors, pSANG15-3F and
pSANG18-3F, were designed without a signal peptide to
allow expression of the scFv and scFv-cys formats in the
cytoplasm. To facilitate disulphide bond formation, the
redox modified bacterial strain Origami 2™ (DE3) was
used. In order to benchmark these clones, we also
expressed the corresponding standard periplasmic scFv
and scFv-AP formats from the pSANG10-3F and
pSANG14-3F vectors respectively in the Origami 2™
(DE3) strain. In conclusion, expression of all constructs in
Origami 2™ cells was compromised relative to BL21
(DE3) cells and there was no evidence of improved
expression using leaderless constructs (Fig 3A,3B) and
these were dropped from further studies.
Table 1: A summary of the pSANG expression vector series, their scFv properties, and E. coli strains used.
Vector Name pSANG10-3F pSANG11-3F pSANG12 pSANG13 pSANG14-3F pSANG15-3F pSANG16 pSANG17 pSANG18-3F
Valency Monovalent Bivalent Monovalent Bivalent Bivalent Monovalent Monovalent Bivalent Monovalent
Epitope 
Tag(s)
6xHis Tri-Flag 6xHis Tri-Flag 6xHis 6xHis 6xHis Tri-Flag 6xHis Tri-Flag 6xHis 6xHis 6xHis Tri-Flag
Site of scFv 
accumulation
Periplasm Periplasm Periplasm Periplasm Periplasm Cytoplasm Cytoplasm Cytoplasm Cytoplasm
Additional 
modifications
None C-terminal 
Cysteine
MBP MBP, C-
terminal 
Cysteine
Bacterial 
Alkaline 
Phosphatase
Leaderless Leaderless, 
MBP
Leaderless, 
MBP, C-
terminal 
Cysteine
Leaderless, C-
terminal 
Cysteine
Expression 
Host tested
BL21(DE3) 
Origami 2
BL21(DE3) BL21(DE3) BL21(DE3) BL21(DE3) 
Origami 2
Origami 2 Origami 2 Origami 2 Origami 2
Protein 
expressed
scFv scFv-cys scFv-MBP scFv-MBP-cys scFv-AP scFv scFv-MBP scFv-MBP-
cys
scFv-cysBMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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From this initial screen there are three useful scFv formats:
scFv, scFv-cys, and scFv-AP derived from the expression
vectors, pSANG10-3F, pSANG11-3F, and pSANG14-3F
respectively.
Direct detection of scFv fused to bacterial alkaline 
phosphatase
Fusion of the scFv to alkaline phosphatase allows direct
detection of binding. ScFv-AP specific for collagen VI,
desmin, and HER2 were grown overnight in auto-induc-
tion medium. After pelleting, and detergent lysis of the
bacteria to release the scFv-AP, the clarified lysate was
diluted in assay buffer and the scFv-AP clones tested
directly for binding to their cognate antigens in ELISA by
adding substrate. The fusion to alkaline phosphatase
means this can be done directly without adding secondary
reagents. This confirmed that the scFv-AP fusions work
very well in a simple direct detection ELISA (not shown).
The scFv-AP format provides a convenient and easy to use
option for probing western blots for the presence of target
antigen. Figure 4A demonstrates the sensitivity of an scFv-
AP clone directed to recombinant human desmin. Dou-
bling dilutions of the antigen were run on an SDS-PAGE
gel and transferred to a PVDF membrane, blocked and
then probed with a single dilution of crude bacterial cell
extract from an overnight induction. The assay was again
developed without the addition of an anti-tag secondary
A comparison of scFv expression using auto-induction media and IPTG induction Figure 2
A comparison of scFv expression using auto-induction media and IPTG induction. A: ScFv expressed from 
pSANG10-3F; B: ScFv-AP expressed from pSANG14-3F. BL21 (DE3) were grown overnight at 30°C using either auto-induc-
tion media (Auto-Ind) or mid-log phase induction with IPTG. The bacterial cell pellet was lysed and analysed by western-blot 
(10 µl/lane) using an anti-histidine tag mouse monoclonal antibody and Cy5 labelled anti-mouse detection system.
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antibody using a standard colorimetric alkaline phos-
phatase substrate, NBT/BCIP. The scFv-AP was able to
detect the presence of antigen down to 0.4 ng/lane.
Figure 4B highlights the utility of the scFv-AP expression
system in offering a simple direct detection system in IHC.
Here strong staining of human collagen VI is demon-
strated at 0.2 µg/ml of scFv-AP (Figure 4B upper panel),
detecting the antibody fragment binding with the addi-
tion of NBT/BCIP colorimetric substrate whereas no stain-
ing is observed with substrate alone (Figure 4B lower
panel). Thus these results demonstrate that direct detec-
tion of alkaline phosphatase fusions is possible in a vari-
ety of applications. It is our experience, however, that
addition of an alkaline phosphatase conjugated second-
ary antibody can be used to increase sensitivity further by
dual labelling with alkaline phosphatase (see below).
Enhanced performance of scFv following dimerisation by 
alkaline phosphatase
A panel of five scFv clones recognising the same epitope of
the breast cancer marker HER2 were used to investigate
the effect of valency/affinity on performance. The affini-
ties of this panel of five scFv clones have been determined
previously [12-14], with a range of equilibrium dissocia-
tion constants (Kd) ranging from a lowest of 320 nM to
the highest at 0.013 nM.
ELISA
Increasing the valency of the HER2 specific scFvs resulted
in a greater sensitivity in an ELISA format. All five scFv
clones were assayed as both monovalent scFv and bivalent
scFv-AP at equimolar concentrations (1 × 10-7 M) on
HER2 coated wells. The monomeric molecular weight for
the scFv-AP construct was used to calculate molarity. Thus
Effect on yield of fusion partner and site of expression Figure 3
Effect on yield of fusion partner and site of expression. Cells were grown overnight at 30°C in auto-induction media 
[11]. The bacterial cell pellet was lysed, clarified and three-fold dilutions of each lysate were analysed by western-blot for the 
protein expression and by ELISA for scFv binding activity. Representative ELISA signals from the linear part of the titration 
curve (1:81 dilution) were plotted relative to those obtained for pSANG10-3F expressed scFv. A: scFv specific for collagen 
type VI; B: scFv specific for desmin (clone C10). A representative western blot showing total protein yield for each scFv format 
is shown in the upper part of panel A and B. The graphs in the lower part of A and B show normalised ELISA data and normal-
ised densitometry values from the western blot MBP: Maltose Binding Protein. AP: Alkaline Phosphatase.BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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Direct detection of scFv binding by using the alkaline phosphatase fusion partner Figure 4
Direct detection of scFv binding by using the alkaline phosphatase fusion partner. A. Direct detection in western-
blot using scFv-AP expressed from pSANG14-3F. Recombinant human desmin directly detected with scFv-AP from bacterial 
cell extract diluted 1:5 using NBT/BCIP. B: Direct detection of collagen VI in immunohistochemical staining of acetone-fixed 
frozen mouse bladder using 0.2 µg/ml scFv-AP detected by NBT/BCIP (upper panel). The lower panel shows the same tissue 
incubated with NBT/BCIP in the absence of an scFv-AP.
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any difference in relative signal is therefore caused by
increased valency rather than quantitative effects of two
detection tags on the bivalent scFv-AP format compared
with one on the standard monovalent format. Binding
was detected by time resolved fluorescence using a euro-
pium-labelled anti-FLAG secondary antibody. The results
shown in Figure 5 clearly demonstrate that the clones
expressed as bivalent scFv-AP exhibit an improved sensi-
tivity in this assay format.
Immunohistochemistry
The same HER2 clones were used to demonstrate the
improved sensitivity of bivalent scFv-AP in immunohisto-
chemical staining of acetone-fixed frozen human breast
carcinoma sections. For example scFv clones, G98A and
C6.5 have equilibrium dissociation constants of 320 and
16 nM respectively. The clones were assayed at identical
protein concentrations and binding detected using anti-
FLAG and a tyramine-DNP amplification system. The
results shown in Figure 6A demonstrate that HER2 stain-
ing for the monovalent clone G98A is weak, although pos-
itive, and for the C6.5 clone, with a 20-fold improvement
in affinity, staining of HER2 is strong. In contrast, staining
of HER2 using G98A as an scFv-AP dimer is as strong as
the monovalent C6.5 clone. The increased avidity for
HER2 generated by making C6.5 bivalent has less effect
probably due to a threshold of affinity required for good
immunostaining by this antibody-epitope combination.
Automated digital image analysis provides a means to
quantify immuno-reactivity in tissue microarrays or tissue
sections. The staining intensities for all five scFv clones
were quantitated and are plotted in Figure 6B.
Western blot
The bivalent scFv-AP format demonstrated superior sensi-
tivity over the monovalent version in detecting desmin
from a recombinant source in western blot. Using anti-
desmin scFv clones as a model, we performed western
blots with dilutions of recombinant human desmin (10,
5, and 1 ng/lane) and probed the blots with purified scFv
and scFv-AP clones diluted, as previously, to equimolar
concentrations (2 × 10-8 M). Binding of the scFv clones
was determined by addition of an anti-FLAG alkaline
phosphatase conjugate (not shown) or an anti-FLAG-HRP
conjugate using ECL western blotting substrate. For the
two anti-desmin clones (Figure 7) the bivalent scFv-AP
demonstrates superior sensitivity over the monovalent
scFv by 2.5-fold and 7.6-fold for clone C10 and D7 respec-
tively, as determined by densitometric analysis of the
western blots. Detection of endogenous desmin in muscle
lysates was also demonstrated (not shown).
Discussion
Phage display and other methods of generating recom-
binant antibodies have proven to be a powerful technol-
ogy for generating antibody specificities. The widespread
adoption of this technology outside of core labs however
has been limited for a number of reasons. This includes
lack of access to clones of desired specificity and problems
of variable levels of production where clones are availa-
ble. Efforts are being initiated to generate and distribute
recombinant clones for the research community e.g. the
Atlas of Protein Expression [15], the Proteome Binders
Consortium [16], and the National Cancer Insititute [17].
To help deal with the issue of production of recombinant
proteins in non-core labs, we have devised a simple vector
system to facilitate production of tagged products. The
system described here utilises auto-induction medium
which does not require user intervention to switch on
recombinant protein expression. In addition all products
have a hexahistidine tag for IMAC purification, with
options for additional detection tags to be added e.g. tri-
FLAG tag as described here.
One particularly useful construct fuses recombinant anti-
body fragments to an optimised variant of bacterial alka-
line phosphatase, a dimeric, periplasmic enzyme. This
allows a simple assessment of production of fusion pro-
tein in culture supernatants or lysates, without the need
for secondary detection reagents, based on alkaline phos-
phatase activity by ELISA. We also demonstrate direct
detection of binding based on alkaline phosphatase in
commonly used assays such as immunohistochemistry
and western blotting (although more sensitive results are
achieved by indirect methods using secondary anti-FLAG
tag reagents).
Effect of alkaline phosphatase fusion on performance in ELISA Figure 5
Effect of alkaline phosphatase fusion on performance 
in ELISA. A series of scFvs, as monomeric scFv or bivalent 
scFv-AP, recognising the same epitope of HER-2 with differ-
ent affinities were tested at equimolar scFv concentration (1 
× 10-7 M) on ELISA wells coated with HER-2. Detection was 
by time resolved fluorescence using Europium-N1 labelled 
anti-FLAG M2 antibody.
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Effect of alkaline phosphatase fusion on performance in IHC Figure 6
Effect of alkaline phosphatase fusion on performance in IHC. A. scFv-APs demonstrate improved sensitivity in IHC. 
HER2 clones are more sensitive when expressed in pSANG14-3F than pSANG10-3F Monovalent G98A, with an affinity of 320 
nM, gave weakly positive staining of the antigen in breast cancer tissue. Whereas, bivalent G98A gave staining equivalent to the 
monomeric scFv clone C6.5, which has a 20-fold higher affinity. Bivalency does not visually improve C6.5 staining. Detection 
was by anti-FLAG antibody coupled to biotin with the addition of streptavidin-horse-radish peroxidase and a tyramine signal 
amplification step. B. Image analysis was used to quantify the staining intensities of all five scFvs as both monomeric scFv and 
bivalent scFv-AP.
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An additional benefit of this construct is that antibody
dimerisation is driven by fusion to alkaline phosphatase.
An alternative version was produced which includes a free
C-terminal cysteine residue which also enables dimerisa-
tion (not shown) as well as facilitating the conjugation of
a reporter molecule such as biotin or FITC [3]. Theoreti-
cally increasing valency has the benefit of increasing bind-
ing affinity of the dimeric molecule. We show this in
practice by comparing alkaline phosphatase fused single
chain Fvs (scFv-AP) with their unfused counterparts in
ELISA, western and immunohistochemistry. This was
done by indirect detection using the tri-FLAG tag present
on all formats. The degree of improvement in sensitivity
for the scFv-AP format over the standard scFv format for
any given assay will be dependent on antibody affinity,
assuming an equal fraction of active recombinant protein
for any given preparation. This was highlighted using a
panel of anti-HER2 scFvs with a range of affinities to the
same epitope. We demonstrated that, when compared on
a molar basis, the alkaline phosphatase fused scFvs were
more active in ELISA. Furthermore, using immunohisto-
chemistry, enhanced staining of HER2 positive breast can-
cer tissue samples was observed with alkaline
phosphatase fused scFvs compared to the monomeric
counterpart. However, the difference in staining dimin-
ished with increasing affinity of the monomeric scFv.
It should be noted, that the standard scFv format can
spontaneously form dimers and higher order multimers.
These multimers are not stable and the proportions of
monomer, dimer, and higher order multimer after purifi-
cation can change over time in storage. The ability of scFvs
to form multimers again is a property of the individual
clones and some are more susceptible than others to this
phenomenon. The degree of multimerisation of the
standard scFv may alter the relative performance of the
scFv when compared to the scFv-AP format.
The performance of the different scFv formats was
assessed in terms of total recombinant protein yield using
a western blot of detergent lysed bacterial pellets to detect
the presence of epitope tagged scFv protein. This gave a
direct comparison of the yield of each of the scFv formats
retained in the cell after production. As a total cell lysate
however, it provides an estimate of the total recombinant
protein produced, including not only the correctly folded
active scFv format but also incorrectly folded, unfolded
and aggregated recombinant protein. Hence the relative
amount of active scFv format in each preparation was also
estimated by measuring the fraction of scFv that was active
in binding to antigen coated ELISA wells. Together the two
results clearly indicate the relative levels of expressed to
active recombinant protein. Although yields vary on a
clone by clone basis, in general the specific activity is rel-
atively constant with the exception of fusions to maltose
binding protein. With MBP, the yield of scFv protein
increased while the binding activity reduced (e.g. Fig 3).
The improvement in total protein may be due to MBP act-
ing to form soluble inclusion bodies [18], which in turn
may limit access of the scFv to antigen.
It is known that leakage of scFv into the culture medium
occurs and this is dependent on the type of growth
medium used for expression. Leakage can even be
enhanced by the addition of sucrose to the growth
medium [19]. It is our experience that the leakage of the
larger scFv fusion proteins (e.g. scFv-AP) is reduced com-
pared to the standard scFv format. By choosing to com-
pare only the recombinant scFv protein retained within
the bacterial cell therefore we may have underestimated
Effect of alkaline phosphatase fusion on performance in Western blot Figure 7
Effect of alkaline phosphatase fusion on performance in Western blot. scFv-APs demonstrate improved sensitivity in 
Western blot. Recombinant human desmin was detected with equimolar concentrations of anti-desmin scFv clone C10 
(applied at a concentration of 2 × 10-8 M) expressed as either scFv or scFv-AP formats. Detection was by anti-FLAG antibody 
coupled to horse-radish peroxidase and addition of ECL western-blotting substrate.BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
Page 11 of 15
(page number not for citation purposes)
the total production, particularly for the standard scFv.
While measurement and recovery of scFv from culture
medium is achievable, it is not a straight forward one-step
Ni-NTA purification procedure [19]. Thus we have delib-
erately chosen to work with the periplasmic fraction to
facilitate concentration and purification of resulting prod-
uct.
Conclusion
We have investigated a number of different scFv formats
for expression and have generated three simple expression
vectors (pSANG10-3F, pSANG11-3F and pSANG14-3F)
for the production of soluble recombinant scFv frag-
ments. These vectors allow rapid cloning of whole popu-
lations of scFv fragments selected from phage display
antibody libraries. They are easily modified to include tags
or reporter molecules of choice. ScFv expression is con-
trolled by growth in a chemically defined auto-induction
medium, which removed the necessity to monitor bacte-
rial growth by optical density. All of the scFv formats pro-
duced from these vectors can be used in a variety of assays
directly from either periplasmic or total cell lysates with-
out the need for purification. One of the vectors,
pSANG14-3F, which produces scFv-fused to alkaline
phosphatase, offers a simple and convenient way of deter-
mining antibody fragment binding in a variety of assay
systems without the need for antibody fragment purifica-
tion and secondary antibody reagent addition. Further-
more, the bivalent scFv-AP has been shown to confer
increased sensitivity over monomeric scFv in ELISA, west-
ern blot, and immunohistochemistry.
Methods
Reagents, scFv clones & bacterial strains
Unless otherwise specified, all restriction endonucleases
and DNA modifying enzymes were obtained from New
England BioLabs (Hitchin, Herts, UK) or Roche Applied
Sciences (Lewes, UK). pMAL-c2x plasmid was obtained
from New England BioLabs (Hitchin, Herts, UK). All elec-
trophoresis and western blotting reagents were obtained
from Invitrogen (Paisley, UK). All the other reagents were
of analytical grade and purchased from Sigma-Aldrich
(Poole, Dorset, UK). E. coli BL21 (DE3) and Origami 2™
(DE3) cells and the pET26b(+) plasmid were from Nova-
gen (San Diego, CA). HER2 specific scFvs were kindly
donated by Dr J. Marks (University of California, San
Francisco). The other scFvs were generated in house to
commercially available antigens purchased from R&D
Systems (MN, USA), USBiologicals (MA, USA) and Pro-
gen (Heidelberg, Germany).
Vector construction
All vectors were constructed using the vector pET26b(+)
(Novagen) as the backbone. pSANG10 and pSANG11 vec-
tors were created by digesting pET26b(+) at the single XhoI
site and at the BglI sites closest to the T7 promoter (by par-
tial digestion) and replacing the fragment with a double
stranded oligonucleotides compatible with these sites,
using four annealed oligonucleotides: CysBgSaS, CysBg-
SaA, SerBgSaS, and SerBgSaA (see Table 2 for all oligonu-
cleotide sequences). This introduces NcoI,  PstI,  NotI,
HindIII restriction sites and a serine (pSANG10) or a
cysteine (pSANG11) immediately after the NotI site. The
resultant pSANG-10 vector sequence between the BglI and
XhoI cloning sites is shown in Figure 1.
pSANG15, the leaderless equivalent of pSANG10, was cre-
ated by replacing the XbaI/NcoI fragment of pSANG10
which contains the pelB  leader sequence, with a short
insert generated from two annealed oligonucleotides:
Leadless and leadlesA. The maltose-binding protein
(MBP) encoding gene from pMAL-c2x was inserted into
pSANG10 at PstI/HindIII sites. The MBP fragment was
amplified using either PstMBP and MBPCysHind or Pst-
MBP and MBPSerHind to include a NotI site at the 5' end
of the fragment, and a cysteine (pSANG12) or a serine
(pSANG13) residue and the hexa-histidine tag at the 3'
end. The insertion of the MBP gene into the leaderless vec-
tor, pSANG15, to create pSANG16 (MBP-ser) and
pSANG17 (MBP-cys) was achieved using the same strat-
egy as above but using NcoMBP as the 5' primer instead of
PstMBP.
The alkaline phosphatase encoding gene was cloned into
PstI/HindIII site of pSANG10 to create pSANG14. Prior to
insertion, we had introduced a silent mutation at nucle-
otide 828 (T→C) to destroy an internal NcoI. This was
achieved by PCR amplification and assembly of the alka-
line phosphatase gene using the products of pstAlkP and
mutAPantisense, and mutAPsense and alkPSerHind prim-
ers. The plasmid pEZZ707 [6] containing a mutant alka-
line phosphatase gene with improved enzymatic activity
were obtained from Dr B. Kay (Argonne National Labora-
tory, USA).
The tri-FLAG epitope tag (Figure 1a) was inserted into
pSANG10, pSANG11, pSANG14 and pSANG15 at the
HindIII site using two annealed oligonucleotides, H3flagA
and H3flagS, to create pSANG10-3F, pSANG11-3F,
pSANG14-3F and pSANG15-3F. Finally, pSANG18-3F
(leaderless plus C-terminal cysteine) was constructed by
cloning the NcoI/NotI, cysteine, hexa-histidine, tri-FLAG
components from pSANG11-3F into the leaderless con-
struct pSANG16. This was done by cloning an NcoI/PvuI
product of pSANG11-3F into the NcoI/PvuI site of
pSANG16 (PvuI is present as a single site within the back-
bone of the original pET26 vector). All of the constructs
were sequenced verified using the T7promoter2 and
T7terminator primers.BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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scFv expression and His-tagged protein purification
Antibody fragment expression was induced using a chem-
ically defined protein expression induction medium [11].
A pre-culture was prepared in MDG media [25 mM
Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM
Na2SO4, 2 mM MgSO4, 10 µM Fe+9, 27.8 mM glucose,
18.8 mM aspartate] containing 50 µg/ml kanamycin. The
MDG media was supplemented with 0.1 mg/ml of leucine
for the Origami 2™ (DE3) strain. The pre-cultures were
then incubated shaking overnight at 30°C. The inocula-
tion of the induction cultures was normalised according
to the optical density of the overnight pre-cultures. The
auto-induction media; ZYM5052 [1% N-Z-amine AS,
0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50
mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 10 µM Fe+9, 54
mM glycerol, 2.8 mM glucose, 5.6 mM α-lactose]; was
supplemented with 50 µg/ml kanamycin and the cultures
were grown overnight at 30°C shaking. To prepare the
total bacterial cell lysate, the cells were pelleted at 3000 ×
g for 10 min., the supernatant was discarded and replaced
by 1/10th of the initial culture volume of BugBuster® rea-
gent containing 25 U/ml benzonase, 2 µl/ml protease
inhibitor cocktail VII and 1.5 U/ml r-lysozyme. The cells
were resuspended and lysed by agitation at room temper-
ature for 10–20 min. and centrifuged at 16,000 × g for 20
min. to pellet the debris.
Where purified scFvs were used, these were generated
from periplasmic extracts purified on Ni-NTA agarose
(Qiagen, Crawley, UK). The periplasmic extracts were pre-
pared by resuspending cells from the overnight induction
cultures in 1/20th of the initial culture volume with TES
[30 mM Tris-HCl pH 8.0; 1 mM EDTA; 20% sucrose (w/
v)] containing 25 U/ml benzonase, 2 µl/ml protease
inhibitor cocktail VII and 1.5 kU/ml r-lysozyme. After 10
min. incubation on ice, the cells were pelleted at 3,000 ×
g for 10 min. and the supernatant was decanted and kept
on ice. The cell pellet was resupended in an equal volume
of 5 mM MgSO4 supplemented with 25 U/ml benzonase,
2 µl/ml protease inhibitor cocktail VII and 1.5 kU/ml r-
lysozyme and incubated on ice for 10 min.; after 10 min.
centrifugation at 3,000 × g, the supernatants were pooled
and a final clarifying spin at 16,000 × g for 20 min. was
performed. The periplasmic extracts were also passed
through a 0.45 µm filter before purification. The Ni-NTA
agarose was equilibrated in 2 × PBS pH 8.0 plus 10 mM
Table 2: A summary of the oligonucleotides used to generate and sequence confirm the pSANG expression vectors.
Primer Designation Primer sequence (5'-3')
CysBgSaS 5'-3cggccatggcccaggtgcagctgcaggcggccgcatgcgcacatcatcatcaccatcacaagctttaataag-3'
CysBgSaA 5'-3tcgacttattaaagcttgtgatggtgatgatgatgtgcgcatgcggccgcctgcagctgcacctgggccatggccggct-3'
SerBgSaS 5'-3cggccatggcccaggtgcagctgcaggcggccgcatccgcacatcatcatcaccatcacaagctttaataag-3'
SerBgSaA 5'-3tcgacttattaaagcttgtgatggtgatgatgatgtgcggatgcggccgcctgcagctgcacctgggccatggccggct-3'
Leadless 5'-ctagaaataattttgtttaactttaagaaggagatatacc-3'
leadlesA 5'-catgggtatatctccttcttaaagttaaacaaaattattt-3'
PstMBP 5'-nnnnnnctgcaggcggccgcaaaaatcgaagaaggtaaactggtaatc-3'
MBPCysHind 5'-nnnnnnaagcttgtgatggtgatgatgatgtgcacaagtctgcgcgtctttcagggcttcatcgac-3'
MBPSerHind 5'-nnnnnnaagcttgtgatggtgatgatgatgtgcagaagtctgcgcgtctttcagggcttcatcgac-3'
NcoMBP 5'-gcccagccggccatggcccaggtgcagctgcaggcggccgcaaaaatcgaagaaggtaaactggtaatc-3'
mut AP sense 5'-gcaacgtaccacggcaatatcgat-3'
mut AP antisense 5'-atcgatattgccgtggtacgttgc-3'
pstAlkP 5'-nnnnnnctgcaggcggccgcaaccccggaaatgcctgttctggaaaaccgg-3'
alkPSerHind 5'-nnnnnnaagcttgtgatggtgatgatgatgtgcagacggtactttcagccccagagcggctttcat-3'
H3flagS 5'-3agctggactacaaagaccatgacggtgattataaagatcatgacatcgattacaaggatgacgatgacaagtaataaa-3'
H3flagA 5'-3agcttttattacttgtcatcgtcatccttgtaatcgatgtcatgatctttataatcaccgtcatggtctttgtagtcc-3'
T7promoter2 5'-gatcgagatctcgatcccgcga-3'
T7terminator 5'-gctagttattgctcagcg-3'BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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imidazole and 40 µl of slurry was added per millilitre of
extract then mixed on a rotary mixer for 1 h at 4°C. The
resin was then washed 5 times by centrifugation in 2x PBS
pH 8.0 plus 20 mM imidazole. The his-tagged scFv were
eluted in 1/10th of initial volume of protein extract in 50
mM Tris, 400 mM imidazole, 500 mM NaCl, pH 8.0. The
samples were dialysed for 24 h at 4°C against PBS pH 8.0
plus 0.01% NaNO3, supplemented with 50 µM ZnSO4
and10 mM MgSO4 for scFv-AP expressed from pSANG14-
3F.
ScFv expression was also performed by induction with 1
mM IPTG. Bacteria were grown in 2TY, 20% glucose, 50
µg/ml kanamycin for approximately 6 h to give an A600
value of 0.5–1.0. The cells were pelleted at 3000 × g for 10
min. and resuspended in an equal volume of 2TY, 50 µg/
ml kanamycin, IPTG 1 mM and incubated overnight shak-
ing at 30°C.
ELISA
Detection of antigen binding by scFvs was conducted by
coating the antigens in 96 well Maxisorp NUNC™
Immuno Plate at 5 µg/ml in phosphate buffered saline
(PBS) or carbonate buffer (pH 9.6) according to the anti-
gen used, 50 µl/well, overnight at 4°C. The wells were
then blocked for 1 h at room temperature with 150 µl of
3% skimmed milk-phosphate buffered saline (M-PBS).
After blocking, the wells were washed 3 times with PBS-
0.1% Tween 20 (PBS-T) and 3 times with PBS. After scFv
induction, dilutions of the total cell lysate or of scFvs puri-
fied from periplasmic extracts were prepared in M-PBS.
Fifty microlitres of blocked scFv was then added to each
well of the ELISA plate and incubated for 1 h at room tem-
perature. The washing step was repeated as above and 50
µl/well of Eu-N1 labelled anti-FLAG M2 antibody (Sigma/
Perkin Elmer, UK) was added at 0.6 ng/µl in M-PBS for 1
h at room temperature. After washing, the plates were
incubated for 10 min. shaking at room temperature with
50 µl of DELFIA® enhancing solution (Perkin Elmer, UK).
The europium signal was read using time resolved fluores-
cence on a Fusion™ instrument (Perkin Elmer, UK). Each
assay was performed in duplicate, with the mean signal
value plotted. When analysing the effect of the fusion
partner choice on yield for a range of scFvs, the ELISA data
were then normalised to the results obtained for the
standard monovalent scFv format (from pSANG10-3F),
i.e. the ELISA score for the monovalent scFv format was
given a value of 1.0 and the ELISA values for the other scFv
formats determined as a fraction of this value. For direct
detection of alkaline phosphatase, the scFv binding step
was followed by the washes as described previously and
supplemented with an extra wash with dH2O. Two hun-
dred microlitres per well of SIGMAFAST™ p-Nitrophenyl
Phosphate was added for 30 min. at room temperature,
and the alkaline phosphatase reaction was read at 405
nm.
SDS-PAGE and densitometry analysis
Proteins were separated by SDS-PAGE in a NUPAGE®
Novex Bis-Tris 4–12% electrophoresis gel. Samples were
loaded at 2 µl per lane and one lane per gel of an scFv
standard was run for quantification. The gel was then
stained with SYPRO® Red protein gel stain following man-
ufacturer's instructions (Invitrogen Paisley, UK). The gel
was visualised on a Typhoon 9410 scanner, the scanned
gels were analysed using ImageQuant TL software (Amer-
sham Biosciences, UK).
Western blot
Recombinant human desmin (Progen, Heidelberg, Ger-
many) and mouse skeletal muscle tissue lysate (Abcam
plc, Cambridge, UK), were diluted in PBS to a final vol-
ume of 10 µl to which was added 4 µl of loading buffer
(containing NUPAGE® LDS sample buffer plus Invitrogen
reducing agent). The proteins were separated under reduc-
ing conditions in NUPAGE® Novex Bis-Tris 4–12%. The
proteins were transferred to an Invitrolon™ PVDF mem-
brane using an electroblotting apparatus, and incubated
for 1 h at room temperature in M-PBS plus 0.1% Tween 20
(M-PBS-T). The membranes were washed 3 times for 5
min. each in PBS plus 0.1% Tween 20 (PBS-T) and incu-
bated with 0.4 µg/ml of anti-histidine tag mouse mAb
(Merck Biosciences Ltd., UK) in M-PBS-T for 1 h at room
temperature on an orbital shaker. After 3 washes of 5 min.
each in PBS-T, the membranes were incubated as
described above but in the dark with 0.4 µg/ml of goat
anti-mouse Cy5 labelled antibody (Amersham Bio-
sciences, UK). Finally, the membrane was washed 3 times
for 5 min. each in PBS-T, once in water for 5 min. and then
air dried. Where anti-FLAG and ECL detection was
required, the membranes were incubated with 0.22 µg/ml
of monoclonal Anti-FLAG® M2 peroxidase (HRP) (Sigma-
Aldrich, Poole, UK) in M-PBS-T for 1 h at room tempera-
ture on an orbital shaker, and ECL western blotting sub-
strate added according to the supplier's instructions
(Pierce, Cramlington, UK). The membranes were scanned
on the Typhoon scanner and analysed using ImageQuant
software. For alkaline phosphatase detection in western
blot, scFv or scFv-AP, expressed from pSANG10-3F or
pSANG14-3F respectively, purified or in diluted crude
bacterial cell lysates were used as the primary antibody as
described above. For indirect detection, 1.1 µg/ml of
mouse monoclonal anti-FLAG® M2-Alkaline Phosphatase
was used as secondary antibody. The detection was per-
formed using SIGMAFAST  ™ NBT/BCIP following the
manufacturer's instructions (Sigma-Aldrich, Poole, UK).BMC Biotechnology 2006, 6:46 http://www.biomedcentral.com/1472-6750/6/46
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Immunohistochemistry
All immunohistochemistry was performed on an auto-
mated immunostainer using supplied reagents unless
stated otherwise (Ventana, Tucson, AZ). For peroxidase
detection, frozen sections were air-dried for 30 min. prior
to fixation in fresh acetone for 15 min. (BDH). Endog-
enous peroxidase was blocked for 20 min. in 0.003%
H202/100% methanol and then transferred to reaction
buffer before the run commenced. The sections were incu-
bated with pSANG10-3F or pSANG14-3F-derived scFv for
12 h at room temperature, before addition of biotinylated
anti-FLAG for 60 min. Detection was effected through
tyramine signal amplification based on tyramine-DNP.
Detection of the deposited biotinylated tyramine and vis-
ualised via a streptavidin-peroxidase conjugate with 3, 3-
diaminobenzidine tetrahydrochloride (DAB) substrate
and copper enhancement giving a brown coloured end
product All slides were counterstained in haematoxylin,
before manual dehydration through alcohols, clearing in
xylene and mounting in DPX. Endogenous biotin was
blocked using an endogenous biotin blocking kit. Non-
specific protein blocks were present in the supplied buff-
ers.
For alkaline phosphatase detection, frozen sections were
air-dried and acetone fixed as before, however endog-
enous peroxidase blocking was replaced with 10 min.
incubation in dual endogenous enzyme block (DAKO UK
Ltd) to block endogenous alkaline phosphatase activity.
pSANG14-3F-generated scFv were incubated for only 1 h
at room temperature, followed by either direct detection
of the bacterial alkaline phosphatase or incubation for 60
min. with anti-FLAG AP. ScFv binding was revealed by 60
min. incubation with NitroBlue Tetrazolium/Bromo-
chloro Indoyl Phosphate (NBT/BCIP) substrate. The link
streptavidin-AP within the kit was not used. Slides were
counterstained with Nuclear Fast Red (Vector Labs, UK)
and mounted in Immu-mount (Thermo Shandon, UK).
Quantitative image analysis
(1) A CCD colour camera (Megaplus ES4.0/E, mounted
on Olympus BX61) was used to capture the tissue sam-
ples, which resulted in a microscopic image (3,800 ×
3,800 pixels, 24BPP) in the form of red-green-blue (RGB)
model. (2) An image pre-processing is performed, where
the image noise and uneven illumination background are
removed by the Gaussian smoothing filter and top-hat fil-
ter respectively [20]. (3) Use of RGB model is problematic
because these three intensities reflect both the absorption
characteristics of the stains used and the amount to which
those stains are present. An alternative to the extraction of
the chromatic information from the image data is the hue-
saturation-intensity (HSI) model. For the HSI model, clas-
sification of stains is based on two dimensions, hue (dom-
inant wavelength) and saturation (purity of the colour). A
region of interest stained with a given colour can, in prin-
ciple, be identified by thresholding the three HSI chan-
nels. At the same time, the intensity value of stains/
expression level can be measured via the corresponding
saturation image. (4) For the fourth stage of the algo-
rithm, the Canny edge detector [21] and properties of tis-
sue morphology are used to distinguish between the
tissue and the slide background. This allows the expres-
sion objects/stains to be characterized and unionized over
structures of interesting tissue in the later step. Finally, the
expression scores are expressed as the labelled stains sig-
nal intensity divided by the presented tissue area.
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